New Treatment Strategy and Future Research Direction for BRAF ‐Mutated Cancer
Cancer Science · 2026-11 · 117 (11) · 2901-2909
DOI: 10.1111/cas.70480 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 23.07.2026. Verfasst von Masanobu Takahashi und 2 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Oncology, Faculty of Medicine, Yamagata University, Yamagata, Japan. Hauptthemen laut MEDLINE: Proto-Oncogene Proteins B-raf, Neoplasms, Protein Kinase Inhibitors, Mutation. Die Arbeit nennt 76 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.
Abstract (Originalsprache)
BRAF is a key oncogene in various malignancies including malignant melanoma, thyroid cancer, colorectal cancer, and lung cancer. The protein it encodes is a constituent of the mitogen‐activated protein kinase pathway that regulates cell growth. Mutations, mainly BRAF V600E , that cause the activation of BRAF in turn induce MEK and ERK activation through their phosphorylation, which promotes the growth and survival of cancer cells. Treatment with BRAF inhibitor, and more recently, treatment with BRAF inhibitor plus MEK inhibitor was first developed in malignant melanoma. In 2022, treatment with BRAF inhibitor plus MEK inhibitor was approved tumor‐agnostically for the treatment of BRAF V600E ‐mutated cancer, apart from colorectal cancer, in the USA. In colorectal cancer, the combination of a BRAF inhibitor and an anti‐EGFR antibody was developed in a later line setting, and more recently, the combination of a BRAF inhibitor, an anti‐EGFR antibody and chemotherapy was developed. Despite the recent advances of BRAF‐targeted therapies, intrinsic and/or acquired resistance to those therapies still needs to be overcome. We discuss the current status of the clinical development of BRAF‐targeted therapy, clinical findings on the resistance mechanism, and new possible treatment strategies for patients with BRAF ‐mutated cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Oncology, Faculty of Medicine, Yamagata University, Yamagata, Japan.
- Department of Clinical Oncology, Tohoku University Graduate School of Medicine, Sendai, Miyagi, Japan.
ORCID-Profile: Masanobu Takahashi
Förderung
- Japan Society for the Promotion of Science
Zitieren
APA
Takahashi, M., Taniguchi, S. H., & Yoshida, Y. (2026). New Treatment Strategy and Future Research Direction for BRAF ‐Mutated Cancer. Cancer Science, 117(11), 2901-2909. https://doi.org/10.1111/cas.70480
Vancouver
Takahashi M, Taniguchi SH, Yoshida Y. New Treatment Strategy and Future Research Direction for BRAF ‐Mutated Cancer. Cancer Science. 2026;117(11):2901-2909. doi:10.1111/cas.70480
BibTeX
@article{Takahashi2026,
author = {Takahashi, Masanobu and Taniguchi, Sakura Hiraide and Yoshida, Yuya},
title = {New Treatment Strategy and Future Research Direction for BRAF ‐Mutated Cancer},
journal = {Cancer Science},
year = {2026},
volume = {117},
number = {11},
pages = {2901--2909},
doi = {10.1111/cas.70480}
}
EUVIMED